Pharmather (CSE: PHRM) is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals.  Pharmather was founded with a particular focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system.  

Their team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets.  

Pharmather’s goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and advance our clinical product pipeline with ketamine and psilocybin in Parkinson’s disease, depression, traumatic brain injury and stroke.  For more information, visit www.pharmather.com.